Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 15 chart positions in 15 markets.
By chart position
- 🇺🇸US · Life Sciences#1215K to 30K
- 🇮🇳IN · Life Sciences#8610K to 30K
- 🇲🇾MY · Life Sciences#1130K to 100K
- 🇮🇪IE · Life Sciences#3910K to 30K
- 🇫🇮FI · Life Sciences#4810K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
27K to 92K🎙 Daily cadence·120 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
90K to 305K🇲🇾33%🇺🇸10%🇮🇳10%+12 more - Active Followers
Loyal subscribers who consistently listen
36K to 122K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking New Treatment Opportunities With a Familiar Target
Jun 5, 2026
Unknown duration
Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma
Jun 3, 2026
Unknown duration
Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care
May 20, 2026
Unknown duration
Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer
May 18, 2026
Unknown duration
KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis
May 15, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/5/26 | The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking New Treatment Opportunities With a Familiar Target | Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care. | — | ||||||
| 6/3/26 | Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma | Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this activity, participants should be better able to: Recognize the rationale for using subcutaneous (SC) formulations of anti-CD38 monoclonal antibodies in patients with multiple myeloma (MM); Assess the clinical profiles of approved and emerging SC formulations of anti-CD38 monoclonal antibodies in patients with MM; and Outline evidence-based, patient-centered strategies for optimizing outcomes with SC formulations of anti-CD38 monoclonal antibodies in patients with MM. | — | ||||||
| 5/20/26 | Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care | Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer. | — | ||||||
| 5/18/26 | Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer | Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to: Evaluate the clinical profiles of first-line immunotherapy-based regimens for the treatment of patients with advanced colorectal cancer (CRC); Formulate strategies to individualize first-line immunotherapy-based regimens for patients with advanced CRC; Describe the clinical evidence on first-line immunotherapy-based regimens for patients with advanced biliary tract cancer (BTC); and Apply patient-, drug-, and disease-specific considerations to optimize first-line immunotherapy-based regimens for patients with advanced BTC. | — | ||||||
| 5/15/26 | KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis | Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM. | — | ||||||
| 5/13/26 | Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings | Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC. | — | ||||||
| 5/12/26 | Sebastien J. Hotte, MD, FRCPC - An Integrated Approach to Optimizing Radioligand Therapy and Bone Health Management in mCRPC | Please visit answersincme.com/NZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sebastien J. Hotte, MD, FRCPC. In this activity, an expert in oncology discusses radioligand therapy for metastatic castration-resistant prostate cancer. Upon completion of this activity, participants should be better able to: Evaluate how the current guidelines and evidence may inform the sequencing of radioligand therapies in patients with metastatic castration-resistant prostate cancer (mCRPC); Apply evidence-based approaches to optimally sequence radioligand therapies in patients with mCRPC; and Identify strategies to optimize bone health management in patients with mCRPC. | — | ||||||
| 5/8/26 | 30-Minute Power Briefing: ICIs in Frontline Advanced Classical Hodgkin Lymphoma—What’s New and What’s Now? | Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated advanced cHL; Interpret the emerging clinical evidence for ICI-based regimens in patients with previously untreated advanced cHL; and Propose how emerging ICI-based regimens, as they become available, may fit into the treatment paradigm for adult and pediatric patients with previously untreated advanced cHL. | — | ||||||
| 5/5/26 | From Burden to Breakthrough: The Rise of KIT D816V-Selective Therapy in Indolent Systemic Mastocytosis | Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM. | — | ||||||
| 4/30/26 | Guidance on Menopause-Related Vasomotor Symptom Management: A Focus on Neurokinin-Targeted Treatment Options | Please visit answersincme.com/NYR860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Liss, MD, MSCP; Denise Black, MD, FRCSC; and Danielle Covarrubias. In this activity, experts in women’s health, joined by a patient advocate, discuss the burden of menopause-related vasomotor symptoms (VMS) and novel management strategies. Upon completion of this activity, participants should be better able to: Identify the impact and burden of VMS as a consequence of menopause; Outline the clinical rationale for novel therapeutic approaches to manage menopause-related VMS; Evaluate the efficacy and safety of novel neurokinin-targeted therapies for treating menopause-related VMS; and Implement patient-centered clinical approaches to improve outcomes for patients experiencing menopause-related VMS. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/27/26 | From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM? | Please visit answersincme.com/860/102653681-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus Berdeja, MD; and Saad Z. Usmani, MD, MBA, FACP, FASCO. In this activity, experts in multiple myeloma (MM) discuss how BCMA bispecific antibody (BsAb)–anti-CD38 monoclonal antibody combinations fit into the treatment paradigm for patients with relapsed/refractory MM. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BCMA BsAbs in combination with anti-CD38 antibodies in the treatment of patients with RRMM; Review the clinical implications of the latest efficacy and safety data for BCMA BsAbs in combination with anti-CD38 antibodies in patients with RRMM; Outline potential considerations for integrating BCMA BsAbs in combination with anti-CD38 antibodies, as they become available, into the treatment of patients with RRMM, in the community setting; and Apply practical tools for optimizing the use of BCMA BsAbs in the community setting. | — | ||||||
| 4/24/26 | Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers | Please visit answersincme.com/AXB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Bijal Shah, MD, MS. In this activity, an expert in oncology discusses B-cell acute lymphoblastic leukemia. Upon completion of this activity, participants should be better able to: Describe the rationale for the development of novel dual CD19 x CD3-targeting bispecific antibodies for patients with relapsed/refractory; B-cell acute lymphoblastic leukemia (R/R B-ALL); Discuss the safety profiles of available and emerging CD19 x CD3-targeting bispecific antibodies; and Design treatment plans for patients with R/R B-ALL that optimize the current and future use of CD19 x CD3-targeting bispecific antibodies. | — | ||||||
| 4/23/26 | Navigating Urologic Cancer Care Across the Map: Getting up to Speed on the Latest Systemic Therapies for Renal Cell Carcinoma and Advanced Urothelial Carcinoma | Please visit answersincme.com/860/240201307-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; and Dorothy Lo, MD, FRCP(C), MHSc, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC. | — | ||||||
| 4/20/26 | Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease | Please visit answersincme.com/860/240201373-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Julie Stakiw, MD, FRCPC; and Constantine S. Tam, MBBS, MD. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss treatment management of high-risk CLL in both the frontline and relapsed/refractory settings. Upon completion of this activity, participants should be better able to: Identify high-risk chronic lymphocytic leukemia (CLL) based on cytogenetic, genomic, and clinical risk factors; Evaluate the latest clinical evidence informing the use of treatments for high-risk CLL in the frontline and relapsed/refractory (R/R) settings; and Apply guideline-concordant, evidence-based strategies to appropriately select and sequence treatments for high-risk CLL in the frontline and R/R settings. | — | ||||||
| 4/15/26 | The ON Switch: Overcoming KRAS Resistance Using Next-Generation Targeted Inhibitors in Advanced NSCLC | Please visit answersincme.com/AZB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Salman R. Punekar, MD, MSc. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses the unmet treatment needs with current RAS(OFF) inhibitors and the potential role for emerging next-generation RAS(ON) inhibitors in KRAS-mutant NSCLC. Upon completion of this activity, participants should be better able to: Describe the persistent unmet needs in KRAS-mutant NSCLC, highlighting treatment gaps across diverse KRAS variants in pretreated advanced settings; Summarize the potential advantages of next-generation RAS(ON) inhibitors versus RAS(OFF) inhibitors; and Evaluate the future positioning of RAS(ON) inhibitors in clinical practice based on emerging evidence. | — | ||||||
| 4/10/26 | The Next Wave of CAR T Innovation for RRMM: Insights Into Emerging GPRC5D-Directed CAR T-Cell Therapies | Please visit answersincme.com/KTB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Krina Patel, MD, MSc. In this activity, Krina Patel, MD, MSc, an expert in multiple myeloma, discusses emerging GPRC5D CAR T-cell therapies in relapse/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the clinical rationale for the use of emerging GPRC5D CAR T-cell therapy in the context of the current treatment landscape for relapsed/refractory multiple myeloma (RRMM); Review the implications of the latest clinical evidence for emerging GPRC5D CAR T-cell therapy in the treatment of patients with RRMM; and Outline potential considerations to optimally integrate GPRC5D CAR T-cell therapies, as they become available, into treatment plans for patients with RRMM. | — | ||||||
| 4/8/26 | Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer | Please visit answersincme.com/FBF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Paolo Tarantino, MD, PhD and Christopher Vetter, MD, MSc, FACS. In this activity, experts in breast cancer discuss the role of neoadjuvant human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugates in HER2+ early-stage breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating the use of anti-HER2 ADCs for the neoadjuvant treatment of HER2-positive early-stage breast cancer; Review the clinical implications of the data for anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer; and Outline clinical, multidisciplinary considerations for the use of anti-HER2 ADCs in the neoadjuvant treatment of HER2-positive early-stage breast cancer. | — | ||||||
| 4/1/26 | Survivorship Strategies for Patients on First-Line HER2+ mBC Maintenance Therapies: Practical Guidance on Monitoring and AE Management | Please visit answersincme.com/860/100850799-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Jane Meisel, MD, FASCO. In this activity, experts in breast cancer discuss practical approaches to optimize survivorship and patient care for patients with HER2-positive metastatic breast cancer who are on first-line maintenance treatment. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC. | — | ||||||
| 3/24/26 | When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice | Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous (IV) formulations in patients with advanced solid tumors; Review the evidence for SC formulations of ICIs compared with IV formulations in patients with advanced solid tumors; and Propose patient-centered strategies for enhancing care with SC administration of ICIs in patients with advanced solid tumors. | — | ||||||
| 3/20/26 | Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change? | Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC. | — | ||||||
| 3/20/26 | HER2 in Focus: Guiding Bladder Cancer Treatment Personalization in the Era of Antibody-Drug Conjugates | Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized, multidisciplinary care for advanced bladder cancer. Upon completion of this activity, participants should be better able to: Apply current guidelines to incorporate biomarker testing into treatment pathways for advanced bladder cancer; Evaluate emerging data on HER2-directed antibody-drug conjugates to guide the management of advanced bladder cancer; and Formulate multidisciplinary treatment plans to support personalized care for patients with HER2-positive advanced bladder cancer. | — | ||||||
| 3/18/26 | Bridging Evidence and Practice: Updates on HER2-Targeted ADCs for Gastric/GEJ Adenocarcinoma | Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugates in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma; and Translate the latest data for the treatment of gastric and GEJ adenocarcinoma within the context of the current treatment landscape. | — | ||||||
| 3/13/26 | Facing Therapeutic Resistance to Maintenance Therapy: The Need for Novel Strategies in HER2+ mBC | Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the rationale for expanding the first-line maintenance therapy options for patients with HR-positive, HER2-positive mBC; and Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC. | — | ||||||
Showing 23 of 133
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
16 placements across 15 markets.
Chart Positions
16 placements across 15 markets.